High Cannabigerol Hemp Extract Moderates Colitis and Modulates the Microbiome in an Inflammatory Bowel Disease Model

Cannabis sativa L. has a long history of medicinal use, particularly for gastrointestinal diseases. Patients with inflammatory bowel disease (IBD) report using cannabis to manage their symptoms, despite little data to support the use of cannabis or cannabis products to treat the disease. In this study, we use the well-described dextran sodium sulfate (DSS) model of colitis in mice to assess the impact of commercially available, noneuphorigenic, high cannabigerol (CBG) hemp extract (20 mg/mL cannabigerol, 20.7 mg/mL cannabidiol, 1 mg/mL cannabichromene) on IBD activity and the colonic microbiome. Mice were given 2% DSS in drinking water for 5 days, followed by 2 days of regular drinking water. Over the 7 days, mice were dosed daily with either high CBG hemp extract or matched vehicle control. Daily treatment with high CBG hemp extract dramatically reduces the severity of disease at the histological and organismal levels as measured by decreased disease activity index, increased colon length, and decreases in percent colon tissue damage. 16S rRNA gene sequencing of the fecal microbiota reveals high CBG hemp extract treatment results in alterations in the microbiota that may be beneficial for colitis. Finally, using metabolomic analysis of fecal pellets, we find that mice treated with high CBG hemp extract have a normalization of several metabolic pathways, including those involved in inflammation. Taken together, these data suggest that high CBG hemp extracts may offer a novel treatment option for patients.

Files

Metadata

Work Title High Cannabigerol Hemp Extract Moderates Colitis and Modulates the Microbiome in an Inflammatory Bowel Disease Model
Access
Open Access
Creators
  1. Benjamin D Anderson
  2. Diana E Sepulveda
  3. Rahul Nachnani
  4. Alonso Cortez-Resendiz
  5. Matthew Coates
  6. Aviauna Beckett
  7. J Bisanz
  8. A Beckett
  9. W Raup-Konsavage
  10. Jordan Bisanz
  11. Joshua J Kellogg
  12. Wesley Raup-Konsavage
Keyword
  1. Inflammatory Bowel Disease
  2. Cannabigerol
  3. Microbiome
  4. Disease Model
  5. Colitis
  6. Cannabis
  7. Hemp Extract
  8. Disease Activity
  9. Dextran Sulfate Sodium
  10. Drinking Water
  11. Cannabis Sativa
  12. Cannabidiol
  13. Inflammation
  14. Cannabichromene
  15. Dextran Sulfate
  16. Diseases
  17. Disease Activity Score
  18. 16s Rrna Gene Sequencing
  19. Tissue Damage
  20. Little Data
  21. Disease Reporting
  22. Colon Length
  23. Medicinal Uses
  24. Daily Drinking
  25. Cannabis Products
  26. Organismal Level
  27. Commercially Available
  28. Genome Analysis
  29. Vehicle Control
  30. Treatment Options
  31. Disease Severity
  32. Metabolic Pathway
  33. Daily Treatment
  34. Fecal Microbiota
  35. Gastrointestinal Diseases
  36. Long History
  37. Treatment Results
  38. Microbiota
  39. Colon Tissue
  40. Novel Treatments
  41. Fecal Pellets
  42. Tissue Injury
  43. Microflora
  44. Rna 16s
  45. Gastrointestinal Disease
  46. Feces Microflora
License CC BY-NC 4.0 (Attribution-NonCommercial)
Work Type Article
Publisher
  1. Journal of Pharmacology and Experimental Therapeutics
Publication Date August 19, 2024
Publisher Identifier (DOI)
  1. 10.1124/jpet.124.002204
Related URLs
  1. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11338277
Deposited February 10, 2025

Versions

Analytics

Collections

This resource is currently not in any collection.

Work History

Version 1
published

  • Created

    February 10, 2025 10:31 by jjk6146

  • Updated

    February 10, 2025 10:31 by [unknown user]

  • Added Creator Benjamin D Anderson

    February 10, 2025 10:31 by jjk6146

  • Added Creator Diana E Sepulveda

    February 10, 2025 10:31 by jjk6146

  • Added Creator Rahul Nachnani

    February 10, 2025 10:31 by jjk6146

  • Added Creator Alonso Cortez-Resendiz

    February 10, 2025 10:31 by jjk6146

  • Added Creator Matthew Coates

    February 10, 2025 10:31 by jjk6146

  • Added Creator Aviauna Beckett

    February 10, 2025 10:31 by jjk6146

  • Added Creator J Bisanz

    February 10, 2025 10:31 by jjk6146

  • Added Creator A Beckett

    February 10, 2025 10:31 by jjk6146

  • Added Creator W Raup-Konsavage

    February 10, 2025 10:31 by jjk6146

  • Added Creator Jordan Bisanz

    February 10, 2025 10:31 by jjk6146

  • Added Creator Joshua J Kellogg

    February 10, 2025 10:31 by jjk6146

  • Added Creator Wesley Raup-Konsavage

    February 10, 2025 10:31 by jjk6146

  • Updated Keyword, Publisher, Publisher Identifier (DOI), and 3 more Show Changes

    February 10, 2025 10:31 by jjk6146

    Keyword
    • Inflammatory Bowel Disease, Cannabigerol, Microbiome, Disease Model, Colitis, Cannabis, Hemp Extract, Disease Activity, Dextran Sulfate Sodium, Drinking Water, Cannabis Sativa, Cannabidiol, Inflammation, Cannabichromene, Dextran Sulfate, Diseases, Disease Activity Score, 16s Rrna Gene Sequencing, Tissue Damage, Little Data, Disease Reporting, Colon Length, Medicinal Uses, Daily Drinking, Cannabis Products, Organismal Level, Commercially Available, Genome Analysis, Vehicle Control, Treatment Options, Disease Severity, Metabolic Pathway, Daily Treatment, Fecal Microbiota, Gastrointestinal Diseases, Long History, Treatment Results, Microbiota, Colon Tissue, Novel Treatments, Fecal Pellets, Tissue Injury, Microflora, Rna 16s, Gastrointestinal Disease, Feces Microflora
    Publisher
    • Journal of Pharmacology and Experimental Therapeutics
    Publisher Identifier (DOI)
    • 10.1124/jpet.124.002204
    Related URLs
    • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11338277
    Description
    • <i>Cannabis sativa</i> L. has a long history of medicinal use, particularly for gastrointestinal diseases. Patients with inflammatory bowel disease (IBD) report using cannabis to manage their symptoms, despite little data to support the use of cannabis or cannabis products to treat the disease. In this study, we use the well-described dextran sodium sulfate (DSS) model of colitis in mice to assess the impact of commercially available, noneuphorigenic, high cannabigerol (CBG) hemp extract (20 mg/mL cannabigerol, 20.7 mg/mL cannabidiol, 1 mg/mL cannabichromene) on IBD activity and the colonic microbiome. Mice were given 2% DSS in drinking water for 5 days, followed by 2 days of regular drinking water. Over the 7 days, mice were dosed daily with either high CBG hemp extract or matched vehicle control. Daily treatment with high CBG hemp extract dramatically reduces the severity of disease at the histological and organismal levels as measured by decreased disease activity index, increased colon length, and decreases in percent colon tissue damage. 16S rRNA gene sequencing of the fecal microbiota reveals high CBG hemp extract treatment results in alterations in the microbiota that may be beneficial for colitis. Finally, using metabolomic analysis of fecal pellets, we find that mice treated with high CBG hemp extract have a normalization of several metabolic pathways, including those involved in inflammation. Taken together, these data suggest that high CBG hemp extracts may offer a novel treatment option for patients.
    Publication Date
    • 2024-08-19
  • Updated

    February 10, 2025 10:31 by jjk6146

  • Updated

    February 10, 2025 10:31 by jjk6146

  • Updated Creator Benjamin D Anderson

    February 10, 2025 10:31 by jjk6146

  • Updated Creator Diana E Sepulveda

    February 10, 2025 10:31 by jjk6146

  • Updated Creator Rahul Nachnani

    February 10, 2025 10:31 by jjk6146

  • Updated Creator Alonso Cortez-Resendiz

    February 10, 2025 10:31 by jjk6146

  • Updated Creator Matthew Coates

    February 10, 2025 10:31 by jjk6146

  • Updated Creator Aviauna Beckett

    February 10, 2025 10:31 by jjk6146

  • Updated Creator J Bisanz

    February 10, 2025 10:31 by jjk6146

  • Updated Creator A Beckett

    February 10, 2025 10:31 by jjk6146

  • Updated Creator W Raup-Konsavage

    February 10, 2025 10:31 by jjk6146

  • Updated Creator Jordan Bisanz

    February 10, 2025 10:31 by jjk6146

  • Updated Creator Joshua J Kellogg

    February 10, 2025 10:31 by jjk6146

  • Updated Creator Wesley Raup-Konsavage

    February 10, 2025 10:31 by jjk6146

  • Added Anderson et al_2024_High Cannabigerol Hemp Extract Moderates Colitis and Modulates the Microbiome.pdf

    February 10, 2025 10:32 by jjk6146

  • Updated License Show Changes

    February 10, 2025 10:32 by jjk6146

    License
    • https://creativecommons.org/licenses/by-nc/4.0/
  • Published

    February 10, 2025 10:32 by jjk6146

  • Updated

    February 10, 2025 21:04 by [unknown user]